Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Organon & Co. Common Stock — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $3.15 (market cap $95.31M), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 37.9× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Organon & Co. Common Stock for 0 Days on average.
| MSTZ | OGN | |
|---|---|---|
Market Cap | $95.31M | $3.61B |
Volume | 60,610,424 | 1,808,049 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $13.81 |
52-Week Low | $2.29 | $5.70 |
Typical Hold Time | 8 Days | 0 Days |
Enterprise Value | — | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $2.69, up 0.37% today, with a bearish technical signal driven by moving averages. Key financial ratios like P/E and P/S are unavailable, limiting fundamental assessment. The stock faces resistance at $3, with support at $2. Recent ETF coverage highlighted leveraged fund performance but lacked direct MSTZ news.
Outlook is cautious due to missing financial data and bearish technicals. Risks include valuation opacity and market volatility. Investment appeal hinges on upcoming earnings clarity and institutional interest, with current sentiment neutral amid limited analyst coverage.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
